UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2022-06, Vol.40 (16), p.1816-1837

2022

Volltextzugriff (PDF)

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

Clinical cancer research, 2017-09, Vol.23 (17), p.4959-4969

2017

Volltextzugriff (PDF)

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx

Journal of clinical oncology, 2019-08, Vol.37 (22), p.1956-1964

2019

Volltextzugriff (PDF)

The Challenge for Development of Valuable Immuno-oncology Biomarkers

Clinical cancer research, 2017-09, Vol.23 (17), p.4970-4979

2017

Volltextzugriff (PDF)

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Journal of clinical oncology, 2016-04, Vol.34 (10), p.1134-1150

2016

Volltextzugriff (PDF)

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Journal of clinical oncology, 2017-08, Vol.35 (24), p.2838-2847

2017

Volltextzugriff (PDF)

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)

Journal of clinical oncology, 2015-01, Vol.33 (1), p.13-21

2015

Volltextzugriff (PDF)

The importance and value of engaging patients in cancer research

Future oncology (London, England), 2021-10, Vol.17 (28), p.3663-3666

2021

Volltextzugriff (PDF)

“Is it cancer or not?” A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ

Cancer, 2022-04, Vol.128 (8), p.1676-1683

2022

Volltextzugriff (PDF)

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities

Clinical cancer research, 2017-09, Vol.23 (17), p.4992-5002

2017

Volltextzugriff (PDF)

Learning to distinguish progressive and non-progressive ductal carcinoma in situ

Nature reviews. Cancer, 2022-12, Vol.22 (12), p.663

2022

Volltextzugriff (PDF)

Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology

Cancer, 2022-01, Vol.128 (2), p.275-283

2022

Volltextzugriff (PDF)

Outcomes and endpoints in cancer trials: bridging the divide

The lancet oncology, 2015, Vol.16 (1), p.e43-e52

2015

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3235-3258

2009

Volltextzugriff (PDF)

How have patient advocates in the United States benefited cancer research?

Nature reviews. Cancer, 2005-01, Vol.5 (1), p.73-78

Collyar, Deborah

2005

Volltextzugriff (PDF)

Community Needs, Concerns, and Perceptions About Health Research: Findings From the Clinical and Translational Science Award Sentinel Network

American journal of public health (1971), 2013-09, Vol.103 (9), p.1685-1692

2013

Volltextzugriff (PDF)

Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions

Frontiers in pharmacology, 2022-10, Vol.13, p.1031992-1031992

2022

Volltextzugriff (PDF)

Aiding the Adoption of Master Protocols by Optimizing Patient Engagement

Therapeutic innovation & regulatory science, 2023-11, Vol.57 (6), p.1136-1147

2023

Volltextzugriff (PDF)

Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells

Breast cancer research : BCR, 2017-11, Vol.19 (1), p.121-121, Article 121

2017

Volltextzugriff (PDF)

Can We Afford to Exclude Patients Throughout Health Technology Assessment?

Frontiers in medical technology, 2022-01, Vol.3, p.796344

2022

Volltextzugriff (PDF)

Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology

Journal of clinical oncology, 2010-05, Vol.28 (15), p.2635-2640

2010

Volltextzugriff (PDF)

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

Journal for immunotherapy of cancer, 2024-06, Vol.12 (6), p.e009063

2024

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition

Journal of clinical oncology, 2002-08, Vol.20 (15), p.3328-3343

2002

Volltextzugriff (PDF)

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review

Breast (Edinburgh), 2020-04, Vol.50, p.95-103

2020

Volltextzugriff (PDF)

Biospecimens and People: A Fundamental Connection

Journal of the National Cancer Institute. Monographs, 2011, Vol.2011 (42), p.41-42

Collyar, Deborah E

2011

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(91)
Buchkapitel
(1)

Sprache

Englisch
(92)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx

The Challenge for Development of Valuable Immuno-oncology Biomarkers

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)

The importance and value of engaging patients in cancer research

“Is it cancer or not?” A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities

Learning to distinguish progressive and non-progressive ductal carcinoma in situ

Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology

Outcomes and endpoints in cancer trials: bridging the divide

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

How have patient advocates in the United States benefited cancer research?

Community Needs, Concerns, and Perceptions About Health Research: Findings From the Clinical and Translational Science Award Sentinel Network

Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions

Aiding the Adoption of Master Protocols by Optimizing Patient Engagement

Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells

Can We Afford to Exclude Patients Throughout Health Technology Assessment?

Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review

Biospecimens and People: A Fundamental Connection

Suchergebnisse filtern